title: Chronic hepatitis C virus infection after treatment for pediatric malignancy.
abstract: Sera of 658 patients who had completed treatment for pediatric malignancy were analyzed by a second-generation enzyme-linked immunosorbent assay and recombinant immunoblot assay test to assess the prevalence of hepatitis C virus (HCV)-seropositivity. All HCV-seropositive patients underwent detailed clinical, laboratory, virologic, and histologic study to analyze the course of HCV infection. One hundred seventeen of the 658 patients (17.8%) were positive for HCV infection markers. Among the 117 anti-HCV+ patients, 41 (35%) were also positive for markers of hepatitis B virus infection with or without delta virus infection markers, 91 (77.8%) had previously received blood product transfusions, and 25 (21.4%) showed a normal alanine aminotransferase (ALT) level during the last 5-year follow-up (11 of them never had abnormal ALT levels). The remaining 92 patients showed ALT levels higher than the upper limit of normal range. Eighty-one of 117 (70%) anti-HCV+ patients were HCV-RNA+, with genotype 1b being present in most patients (54%). In univariate analysis, no risk factor for chronic liver disease was statistically significant. In this study, the prevalence of HCV infection was high in patients who were treated for a childhood malignancy. In about 20% of anti-HCV+ patients, routes other than blood transfusions are to be considered in the epidemiology of HCV infection. After a 14-year median follow-up, chronic liver disease of anti-HCV+ positive patients did not show progression to liver failure.
authors.affiliation: Department of Pediatrics, Università di Padova, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Cesaro
authors.forename: M G
authors.initials: MG
authors.lastname: Petris
authors.forename: F
authors.initials: F
authors.lastname: Rossetti
authors.forename: R
authors.initials: R
authors.lastname: Cusinato
authors.forename: C
authors.initials: C
authors.lastname: Pipan
authors.forename: M
authors.initials: M
authors.lastname: Guido
authors.forename: L
authors.initials: L
authors.lastname: Masiero
authors.forename: G A
authors.initials: GA
authors.lastname: Botta
authors.forename: G A
authors.initials: GA
authors.lastname: Meloni
authors.forename: L
authors.initials: L
authors.lastname: Zanesco
mesh_terms: D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D015415:Biomarkers; D001706:Biopsy; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006508:Hepatitis Antibodies / Q000097:blood; D006509:Hepatitis B / Q000201:enzymology / Q000453:epidemiology / Q000635:transmission; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis / Q000201:enzymology / Q000453:epidemiology* / Q000635:transmission; D003699:Hepatitis D / Q000201:enzymology / Q000453:epidemiology / Q000635:transmission; D003698:Hepatitis Delta Virus / Q000276:immunology; D006518:Hepatitis Viruses / Q000276:immunology / Q000302:isolation & purification; D006521:Hepatitis, Chronic / Q000150:complications / Q000175:diagnosis / Q000201:enzymology / Q000453:epidemiology*; D006801:Humans; D008099:Liver / Q000473:pathology; D017093:Liver Failure / Q000453:epidemiology / Q000209:etiology; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000628:therapy; D015995:Prevalence; D012367:RNA, Viral / Q000097:blood; D012307:Risk Factors; D065227:Transfusion Reaction
chemical_list: D015415:Biomarkers; D006508:Hepatitis Antibodies; D012367:RNA, Viral; D000410:Alanine Transaminase